Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease.
There is a high prevalence of diseases caused by human papillomavirus (HPV) infection. Unfortunately, current treatments are inadequate. However, because there is evidence to support a role for the immune system in host defence against this virus, an immunotherapeutic approach is warranted. The existing immunotherapies are not completely effective, nor are they durable. In addition, natural history studies associated with spontaneous regression have provided little guidance to the design of successful interventions. This state of knowledge has encouraged efforts towards the development of novel immunotherapeutic strategies. Successful preclinical studies of therapeutic vaccine candidates have led to clinical studies for a variety of HPV-associated indications, such as anogenital warts and cervical and anal intraepithelial neoplasia. Immunisation approaches such as adjuvanted peptides, virus-like particles and fusion constructs are discussed. Specifically, chimaeric molecules comprised of mycobacterial heat-shock proteins (Hsps) and HPV16 E7 appear promising.
Chu
N Randall
NR
Stressgen Biotechnologies Corp., 350-4243 Glanford Ave, Victoria, BC, Canada, V8Z 4B9. rchu@stressgen.com
D000818:Animals; D006801:Humans; D018928:Immunity, Mucosal; D009092:Mucous Membrane / Q000276:immunology / Q000821:virology; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D014412:Tumor Virus Infections / Q000276:immunology / Q000517:prevention & control*; D014611:Vaccination / Q000379:methods; D014765:Viral Vaccines / Q000494:pharmacology / Q000627:therapeutic use*
D014765:Viral Vaccines